The Pediatric Neuroblastoma Treatment Market is predicted to reach US$ 1,863.1 million by 2031 from US$ 759.5 million in 2020, and to grow at a CAGR of ~8.5% between the forecast period 2021 to 2031.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2021 to 2031. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2020. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
Treatment Type [Chemotherapy, Immunotherapy, Targeted Therapy, and Radiation Therapy], Risk Group [Low Risk, Intermediate-Risk, and High Risk], End User [Hospital and Cancer Specialty Center]
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Bayer AG, Pfizer Inc., Apeiron Biologics AG., United Therapeutics Corporation, Y-mAbs Therapeutics, Inc., Cellectar Biosciences, Inc., Clarity Pharmaceuticals, Provectus Biopharmaceuticals, Inc., and Scorpion Therapeutics, among others.
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2031
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Pediatric Neuroblastoma Treatment - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Pediatric Neuroblastoma Treatment - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Pediatric Neuroblastoma Treatment - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Pediatric Neuroblastoma Treatment - ANALYSIS & FORECAST, BY REGION
North America Pediatric Neuroblastoma Treatment
1. North America Pediatric Neuroblastoma Treatment , by Country
1. US
2. Canada
1. North America Pediatric Neuroblastoma Treatment , by Product
2. North America Pediatric Neuroblastoma Treatment , by Type
3. North America Pediatric Neuroblastoma Treatment , by Gender
4. North America Pediatric Neuroblastoma Treatment , by Sales Channel
3. Europe Pediatric Neuroblastoma Treatment
1. Europe Pediatric Neuroblastoma Treatment , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Pediatric Neuroblastoma Treatment , by Product
3. Europe Pediatric Neuroblastoma Treatment , by Type
4. Europe Pediatric Neuroblastoma Treatment , by Gender
5. Europe Pediatric Neuroblastoma Treatment , by Sales Channel
4. Asia Pacific Pediatric Neuroblastoma Treatment
1. Asia Pacific Pediatric Neuroblastoma Treatment , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Pediatric Neuroblastoma Treatment , by product
3. Asia Pacific Pediatric Neuroblastoma Treatment , by Type
4. Asia Pacific Pediatric Neuroblastoma Treatment , by Gender
5. Asia Pacific Pediatric Neuroblastoma Treatment , by Sales Channel
5. Rest of the World Pediatric Neuroblastoma Treatment
1. Rest of the World Pediatric Neuroblastoma Treatment , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Pediatric Neuroblastoma Treatment , by Product
3. Rest of the World Pediatric Neuroblastoma Treatment , by Type
4. Rest of the World Pediatric Neuroblastoma Treatment , by Gender
5. Rest of the World Pediatric Neuroblastoma Treatment , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 26
Price : US$ 3160 |
Date : Nov 2024 |
Category : Automotive |
Pages : 211 |
Price : US$ 3160 |
Date : Nov 2024 |
Category : Automotive |
Pages : 207 |
Price : US$ 3160 |
Date : Nov 2024 |
Category : Automotive |
Pages : 203 |
Price : US$ 3460 |
Date : Nov 2024 |
Category : Automotive |
Pages : 217 |